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Summary
Objective: Small proteoglycans (PGs) may accumulate in late stage osteoarthritis even as aggrecan is lost. It is not clear what role
transforming growth factor (TGF) beta has in this accumulation. Our goal was to investigate the ability of TGF beta 1 to modulate the
synthesis and accumulation of decorin, biglycan, and fibromodulin in cartilage explants cultured under conditions in which aggrecan
synthesis remains relatively constant.
Design: Articular cartilage was cultured in the presence or absence of 4 ng/ml TGF beta 1 for up to 16 days. Material extracted from cartilage
was assayed for 35SO4-large and small PGs and for total endogenous decorin, biglycan and fibromodulin.
Results: The synthesis of 35SO4-small PGs increased during the 16 days in culture in response to TGF beta 1, but declined in control
cultures. The difference in 35SO4-decorin between TGF beta 1 and control samples reached nine-fold after 16 days, while the difference in
total endogenous decorin was less than 1.5-fold. 35SO4-decorin, which was present in TGF beta 1-treated cultures had an identical core
protein, but a longer glycosaminoglycan chain than that of decorin in control cultures. No significant differences in endogenous biglycan were
detected, but accumulation of fibromodulin in TGF beta 1 explants exceeded fibromodulin in controls, on average, by 3.8-fold. Fibromodulin
was present in cartilage in both keratan sulfate- and non-sulfated oligosaccharide-substituted forms.
Conclusions: The accumulation of each of the three small PGs was affected to a different extent in response to TGF beta 1. Of the three,
fibromodulin content was most rapidly augmented in response to TGF beta 1.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
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Introduction
Decorin, biglycan, and fibromodulin are members of the
small, leucine-rich proteoglycan (PGs) (SLRP) family of
proteins and are located in articular cartilage as well as in
other tissues1,2. Both decorin and fibromodulin have been
localized by electron microscopy to collagen fibrils in carti-
lage. In in vitro studies, decorin and fibromodulin influence
the rate and extent of collagen type I fibrillogenesis. A direct
role in control of type I collagen fibrillogenesis in the tendon
has been confirmed for fibromodulin by observation of
fibromodulin-null mice3 and for decorin, both by obser-
vations of decorin-deficient mice4 and by disruption of
decorin–fibronectin–collagen interactions in vivo using
blocking peptides5. Thus, it is reasonable to think that the
function of decorin and fibromodulin in cartilage is to
regulate the diameter and organization of collagen fibrils,
although this has not been directly confirmed.
Decorin, biglycan, and fibromodulin bind to active trans-
forming growth factor (TGF) betas 1, 2 and 3 via their core
proteins, with both high-affinity and low-affinity binding
sites6. The chondroitin/dermatan sulfate chains of decorin
and biglycan appear to somewhat hinder this binding,
making TGF beta binding to fibromodulin more effective
than binding to decorin or biglycan within the tissue. In
the study by Hildebrand et al.6, this binding was specific
for TGF beta out of several other growth factors tested
and suggests an important role for these small PGs in
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regulating the activity of TGF beta on the synthesis of
matrix components. Studies by Markmann et al.7 suggest
that decorin must be bound to matrix in order to sequester
and inactivate TGF beta.
In turn, TGF beta contributes to the regulation of the
synthesis of the small PGs. This has been studied in
chondrocyte cell cultures. Several investigators have re-
ported that TGF betas increase the synthesis of the small
PGs in cultures of isolated chondrocytes. Decorin and
biglycan have typically been the focus of these studies, but
reports have been inconsistent as to whether one or the
other, or both are elevated. Roughley et al.8 reported a
decrease in decorin mRNA in chondrocytes cultured with
TGF beta in monolayers and Demoor-Fossard9 reported
that TGF beta inhibited decorin synthesis in chondrocyte
monolayers, but not in chondrocytes in alginate beads.
There is no information about the effect of TGF beta on
fibromodulin in chondrocytes, with the exception of prelimi-
nary data showing two-fold increases in fibromodulin at the
RNA and protein level in chondrocytes cultured in alginate
beads10.
Recent studies have focused on the SLRP in osteo-
arthritic cartilage. In vivo, Cs-Szabo´ et al.11 have shown
that mRNA for aggrecan, decorin, biglycan, and fibro-
modulin are increased in human knee osteoarthritis (OA),
while Dourado et al.12 reported similar increases for the
canine anterior cruciate ligament transection model. Both
laboratories reported greater changes in biglycan than in
decorin (10:5.8 and 3.9:1.2, respectively). Fibromodulin
mRNA was reported to increase by 11.5- and 2.4-fold,
respectively. Cs-Szabo´ reported comparable increases at
the protein level as well as for decorin, biglycan, and
fibromodulin. Little et al.13 reported increased decorin and
biglycan synthesis in lateral tibial and femoral cartilage
after a lateral meniscectomy in sheep. Most recently, Bock
et al.14 reported increased transcription and translation of
both decorin and biglycan in late stage human OA, with
highest levels in areas adjacent to the lesion. On the other
hand, Poole et al.15 reported no overall differences in
biglycan and decorin contents in human knee OA, although
loss from the superficial layers of osteoarthritic cartilage
was greater.
A role for TGF betas and small PGs, possibly related, in
OA progression is under consideration. TGF beta has been
implicated in synovitis16, in OA progression17,18, and osteo-
phyte formation. Furthermore, chondrocytes from OA carti-
lage may be more responsive to TGF beta than normal
chondrocytes19. The accumulation of small PGs in human
cartilage in late stage OA11 would increase the potential to
bind and sequester TGF beta and possibly mitigate effects
on OA6. However, bound and sequestered TGF beta would
fail to stimulate synthesis of the small PGs and other matrix
components required to maintain a healthy cartilage. Thus,
the consequences are really not known, and could be
positive or negative outcomes for OA.
Studies that have been done to better define the relation-
ship among TGF beta, chondrocyte synthesis of small PGs,
and OA have not been altogether consistent, but at least
some of the confusion must be attributed to the focus on
chondrocytes in culture. Chondrocytes in monolayer rapidly
dedifferentiate. Even chondrocytes in three-dimensional
cultures fail to mimic the in vivo chondrocyte in all re-
spects20. Explant cultures, with intact, native matrix, pro-
vide conditions closer to in vivo. Our laboratory has a
well-characterized explant culture system in which aggre-
can remains constant, but fibronectin, an early marker of
degenerating cartilage, accumulates21. Preliminary data
suggested increased synthesis of total small PGs as well.
Our goal was to determine the effect of TGF beta 1
individually on each of the small PGs, decorin, biglycan,
and fibromodulin, in this system.
Materials and methods
MATERIALS
L-[35S]methionine (1200 Ci/mmol) and Na235SO4 (25–
40 Ci/mg) and L-[4,5-3H] leucine were purchased from
Amersham (Arlington Heights, IL). Peroxidase-linked goat
anti-mouse IgG, and peroxidase-linked goat anti-rabbit IgG
were purchased from Cappel Biomedicals (Westchester,
PA). Hams F12 and Gey’s balanced salt solutions were
from GIBCO (Grand Island, NY). ITSCR+ serum-free
supplement was from Collaborative Biomedical Products
(Bedford, MA). Human recombinant TGF beta 1 was pur-
chased from Life Technologies (Gibco, BRL) as powder
lyophilized from 5 mM HCl containing 50 µg of human
serum albumin per microgram of the cytokine and recon-
stituted with sterile H2O. All storage vessels and pipette tips
used to handle stock of TGF beta 1 were silanized.
Antibodies to canine biglycan and decorin10 and cross-
reactive purified polyclonal antibody raised against a
C-terminal amino acid sequence of human fibromodulin22
were prepared. Canine biglycan and decorin cDNAs were
sequenced and specific peptide sequences were selected
from the C-terminal of biglycan and decorin (Gene bank
accession numbers: Canine biglycan, U83140; Canine
decorin, U83141). Synthetic peptides were coupled with
ovalbumin and injected to rabbits. Polyclonal anti-sera
were purified on affinity columns on which the correspond-
ing peptides were bound10. The anti-human fibromodulin
antibody preparation has been described previously22 and
cross-reacted with canine fibromodulin. The anti-decorin
monoclonal antibody, 6D623,24, used for immunoprecipi-
tation, was the gift of Dr Paul Scott (Edmonton, Alberta,
Canada). Nitrocellulose membranes were obtained from
Osmonics (Westborough, MA). Hybond™–N+ membranes
were obtained from Amersham Pharmacia Biotech Limited
(Little Chalfont, Buckinghamshire, England).
Methods
EXPLANT CULTURE
Source of explant cartilage
The sources of cartilage were Labrador Retrievers or
Labrador Retriever–Greyhound crosses from a colony
maintained at the James A. Baker Institute for Animal
Health and bred for the study of genetic markers of canine
hip dysplasia and its concomitant OA. Dogs ranged in age
from 8 to 28 months.
Culture conditions
Cartilage was obtained at necropsy from Labrador re-
trievers from our colony of dogs with individuals at high and
low risk for developing OA. Only macroscopically disease-
free cartilage was removed aseptically from the hip, knee,
or shoulder joints of these Labrador Retriever dogs and
placed into Gey’s balanced salt solution; however, some
cartilage sampled may be predisposed for development of
cartilage damage25,26. The cartilage was rinsed three times
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and approximately 50 mg was placed into screw-capped
vials or 24-well tissue culture dishes (Corning, NY) contain-
ing 2 ml of the appropriate culture medium. All explants
were incubated in Hams F12 nutrient medium supple-
mented with ITSCR+ and with CaCl221. In some experi-
ments, Na2SO4 was added to a concentration of 0.3 or
1.6 mM to be certain that available sulfate was not limiting
for PG synthesis. Cartilage was cultured for 1 or 15 days
with 4 ng/ml TGF beta 1, following 1–2 days of preincu-
bation. Controls were cultured for the same length of time
in the absence of TGF beta. The dosage chosen is physio-
logically relevant. TGF beta 1 levels in synovial fluids from
OA patients varied widely in one study, reaching as high as
10 ng/ml and averaging to about 2.5 ng/ml27. Furthermore,
4 ng/ml of TGF beta was shown previously to stimulate
aggrecan synthesis under the basal conditions28, but not
under the serum-free supplementation used in these
experiments21. However, at this dosage, the synthesis of
other proteins, especially fibronectin, is markedly af-
fected21. In preliminary experiments, addition of vehicle
alone had no effect on cartilage metabolism. Medium was
changed every 3 or 4 days at which time fresh TGF beta
was added. Radioactive precursors (35SO4 or 3H-leucine
plus 35S-methionine) were added to the culture on the day
before harvest. After an overnight incubation, explants
were washed three times with Gey’s balanced salt solution
and frozen until further analyses.
EXTRACTION AND QUANTITATION OF TOTAL PGS
Cartilage was extracted with 4 M urea in 0.05 M phos-
phate buffer, pH 7.4, or with 4 M guanidinium chloride in
0.05 M acetate buffer, pH 5.8, in the presence of a cocktail
of protease inhibitors (0.3 mM benzamidine, 20 mM ethyl-
enediamine tetraacetate (EDTA), 10 mM N-ethylmaleimide,
0.4 mM phenylmethylsulfonylfluroide, final concentrations).
To determine total PG synthesis, the cartilage residue after
extraction was digested with 1 mg/ml papain in 0.05 M
phosphate buffer containing 0.0326% N-acetylcysteine and
2 mM EDTA at 60°C for 4 h, and aliquots of digests and
extracts were added to Ecoscint (National Diagnostics,
Atlanta, GA) and quantitated in a Beckman LS6800 liquid
scintillation counter. Total sulfated glycosaminoglycans
(GAG) in the extracts and papain digests were determined
by the dimethylmethylene blue (DMMB) assay of
Farndale29.
PURIFICATION, CHARACTERIZATION, AND QUANTITATION OF
NEWLY SYNTHESIZED PGS
For characterization of 35SO4-PG and 3H/35S-PG, urea
and/or guanidinium chloride extracts were applied to a
DEAE ion exchange column (DE52 cellulose) in 6 M urea,
0.05 M Tris–HCl, pH 7.5, 0.1 M NaCl. Columns were eluted
with 0.2, 0.3, and 1.0 M NaCl in 6 M urea, 0.05 M Tris–HCl,
pH 7.5, and the 0.3 and 1.0 M NaCl fractions were ana-
lyzed by gradient gel electrophoresis and detected by
autoradiography or Western analysis.
Release of free GAG chains
To analyze free GAG chains, guanidinium chloride ex-
tracts were subject to gel filtration chromatography on
Sepharose CL6B. Fractions corresponding to aggrecan
and to the small PGs with GAG substitution were pooled
separately, transferred to digest buffer and digested for 4 h
at 60°C with 0.5 mg/ml papain. The samples were centri-
fuged and made 5% with potassium acetate in 95%
ethanol. The 35SO4-GAGs were precipitated over 2 days at
4°C and then washed with ethanol, dried, redissolved in
distilled, deionized water, prepared for electrophoresis, and
were detected by autoradiography.
Immunoprecipitation of decorin
The 0.3 M NaCl fractions from DEAE anion exchange
columns were transferred to a dilution buffer (10 mM phos-
phate buffer, pH 7.2, containing 0.5% Na deoxycholate, 1%
Triton X-100, 0.1% SDS, 100 mM NaCl, and 1 mM EDTA)
and incubated overnight with monoclonal antibody 6D6 or
with a control antibody at 4°C. The immune complex was
precipitated with protein G agarose. Samples were then
washed three times in 20 mM Tris buffer, pH 8.8, containing
0.5% Na deoxycholate, 0.5% NP 40, 50 mM NaCl, 2 mM
PMSF, and 2 mM EDTA. Immunoprecipitated small PGs
were resolved by SDS gradient gel electrophoresis30 after
heating at 95°C for 10 min in digestion buffer (50 mM Tris,
pH 6.8, 2% SDS, 2 mM PMSF, and 2 mM EDTA), and were
visualized by autoradiography.
PURIFICATION, CHARACTERIZATION, AND QUANTITATION OF
ENDOGENOUS SMALL PGS
For purification, characterization, and quantitation of total
decorin, biglycan, and fibromodulin, the guanidinium
chloride extracts were directly analyzed by Western
analysis before and after enzymatic digestion.
Enzymatic digestion
For the analysis of biglycan, decorin, and fibromodulin
core proteins, samples of the extracts (20–40 µg dry
weight) were dialyzed to 0.1 M Tris, 0.05 M Na-acetate, pH
7.3, and were digested with 20 mU proteinase-free chon-
droitinase ABC (Seikagaku) at 37°C overnight to remove
chondroitin sulfate or dermatan sulfate side chains from the
core proteins of decorin and biglycan. After adjusting the
pH to 6.0, one-half of the samples were further digested
with Keratanase II (Seikagaku) in the presence of protein-
ase inhibitors at 37°C overnight, to remove keratan sulfate
(KS) side chains from the core protein of fibromodulin.
One-half of this sample was further digested with
N-glycanase [PNGase F; New England BioLabs, Inc.
(Beverly, MA)] according to the manufacturer’s instructions,
to remove N-linked substitution from the core proteins of
fibromodulin.
SODIUM DODECYL SULFATE–POLYACRYLAMIDE GEL
ELECTROPHORESIS (SDS–PAGE), AUTORADIOGRAPHY, AND
WESTERN BLOTTING
Small PGs and their core proteins were separated in
12% uniform or 4–15% gradient slab gels under reducing
conditions using the Tris/glycine buffer system described by
Laemmli31. Gels were stained with Coomassie brilliant blue
and/or toluidine blue, or were electrophoretically trans-
ferred onto nitrocellulose for free core proteins or onto
Hybond–N+ nylon membranes for native PGs.
Autoradiography
Stained gels were dried and exposed to a phosphorim-
ager screen. Radioactive PGs and core proteins were
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quantitated using MACBAS software (Fuji Medical Systems
USA, Stamford, CT) after scanning in the Fujix B10-Imaging
Analyzer.
Western blot hybridization
Membranes containing transferred proteins were blocked
with 5% milk in Tris buffered saline containing Tween 20,
and were probed with antibodies to decorin, biglycan, or
fibromodulin followed by peroxidase-labeled goat anti-
rabbit IgG and visualized by enhanced chemiluminescence
assay (ECL) followed by quantitation of the signal on ECL
films by a BioRad image analyzer.
STATISTICAL METHODS
Results were analyzed by ANOVA, general linear model,
using MINITAB software (Kent, Boston, MA). Significance was
set at P<0.05.
Results
PROTEOGLYCAN SYNTHESIS IN CARTILAGE EXPLANTS
When cartilage explants were cultured in the presence of
TGF beta 1 and supplemented with insulin and calcium,
total 35SO4-PG was unchanged or only modestly in-
creased, but 35SO4-PG in a 4 M urea extract was increased
several folds with respect to control cultures (Table I).
Analysis of urea extracts by gel filtration chromatography,
DEAE chromatography, and gradient gel electrophoresis
showed that 35SO4-small PG are predominant in urea
extracts, although additional material, presumably aggre-
can, is present at the top of the gel (data not shown).
Further analysis was performed on both urea and guanidin-
ium chloride extracts of cartilage explants in an attempt to
characterize the effect of TGF beta1 on synthesis and
accumulation of the small PGs, decorin, biglycan, and
fibromodulin.
CHARACTERIZATION AND QUANTITATION OF NEWLY SYNTHESIZED
SMALL PGS BY AUTORADIOGRAPHIC ANALYSIS
After 2 days in culture, control cartilage synthesized
35SO4-small PGs or 3H/35S-small PGs, which co-migrated
with endogenous decorin and biglycan identified by
Western analyses (data not shown). Decorin was the
predominant small 35SO4-PG and eluted from DEAE anion
exchange columns with 0.3 M NaCl (Fig. 1, lanes 4 and 6).
Explant culture was continued for an additional 14 days in
the presence or absence of TGF beta 1. By day 16,
synthesis of 35SO4-small PGs was increased in TGF beta-
treated samples. A three-fold increase in total small PG
synthesis relative to day 2 controls (4471/1566, Table II),
and as much as a nine-fold increase relative to day 16
Fig. 1. Autoradiograph of small PGs in control and TGF beta
1-treated cartilage explants. This figure contrasts newly synthe-
sized small PGs in control cultures after 2 days with small PGs in
TGF beta 1-treated cultures after 16 days. Small PGs were purified
by DEAE anion exchange chromatography and analyzed by SDS/
PAGE and autoradiography. From left to right, lanes 1–4 show
anion exchange fractions of proteins labeled with 35SO4-GAG and
lanes 5–8 show anion exchange fractions of proteins labeled with
a combination of 3H-leucine and 35S-methionine. The numbers
between lanes 1–4 and 5–8 indicate the positions of molecular
weight markers. Fractions in lanes 1, 3, 5, and 7 were digested
with chondroitinase ABC prior to electrophoresis (+C). Fractions in
lanes 2, 4, 6, and 8 were intact (−C). Lanes 1, 2, 7, and 8 are 1.0 M
NaCl DEAE fractions from 16-day TGF beta 1-treated cultures
(TGF d16). Lanes 3, 4, 5, and 6 are 0.3 M NaCl DEAE fractions
from 2-day control cultures (Contr d2). Increased synthesis of
small PG in response to TGF beta 1 is apparent (compare lane 2
with lane 4, and lane 8 with lane 6). The data also show that both
small PGs in day 2 control cultures, and the highest molecular
weight small PGs in day 16 TGF beta-treated cultures were
completely digested by chondroitinase ABC (see lanes 1 and 3,
and lanes 5 and 7), leaving core proteins of identical molecular
weight (compare lane 5 with lane 7). The open arrow points to
intact decorin. The closed arrow points to intact, high molecular
weight decorin synthesized in the presence of TGF beta 1.
Table I
Proteoglycans in cartilage explants cultured in the presence or absence of TGF beta 1
Total 35SO4-PG (cpm/mg
wet weight)
35SO4-PG in urea (% of
total)
Total PG (µg/mg wet) PG in urea (% of total)
Control (16) 7139±3502 2.6±2.2 44.1±11.2 4.9±1.9
+TGF beta 1 (16) 7550±2644 8.1±2.3 37.3±8.4 6.4±2.5
P0.542 P<0.001 P0.056 P0.012
The data in this table compare total endogenous and newly synthesized PGs after 16 days in culture with endogenous and newly
synthesized PGs that are easily extracted from articular cartilage with 4 M urea. Cartilage was cultured in the presence or absence of 4 ng/ml
TGF beta 1. On day 15, cartilage was pulsed for 1 day with Na235SO4. At harvest, cartilage was extracted with urea and the residue digested
with papain. An aliquot of each urea extract and papain digest was counted in a liquid scintillation (35SO4-PG) counter or assayed for GAG
content with the DMMB assay (PG). The data represent four different experiments (four different donor animals), with four replicates from
each experiment, such that the number in parenthesis indicates the total number of replicates for each group. The data were analyzed by
two-way ANOVA, general linear model, with respect to dog and treatment.
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controls (4471/494, Table II), were noted. Furthermore,
much of the small PG synthesized after 16 days of culture
in the presence of TGF beta 1 had a higher molecular
weight (HMW) than that of decorin found in the controls
(Fig. 1, lanes 2 and 8; Table II). It was extracted from
cartilage by either urea or guanidinium chloride, and was
eluted from DEAE anion exchange columns in both the
0.3 and 1.0 M NaCl fractions. Although 35SO4-small PG
synthesis decreased in the controls, a small shift in
molecular weight was also evident (Table II). The GAG
chains of the HMW small PG synthesized in the presence
of TGF beta 1 were sensitive to chondroitinase ABC
digestion (Fig. 1, lanes 1 and 7), and the core proteins were
identical in electrophoretic mobility to those obtained from
the small PGs synthesized in the controls (Fig. 1, lanes 5
and 7).
The data are consistent with identification of the HMW
35SO4-PG as decorin with a longer GAG chain. The newly
synthesized, HMW small PG could be immunoprecipitated
by an anti-decorin antibody (not shown). Electrophoretic
analysis of the free GAG chains after papain digestion
indicated that GAG chains on the small PGs from TGF
beta-treated samples ranged from 25 to 50 kDa and, on
average, were 1.5 times the size of the GAG chains from
the small PGs synthesized in day 2 controls and twice the
size of the GAG chains from all aggrecans (not shown).
Furthermore, when synthesis of core proteins were fol-
lowed with radioactive amino acid precursors, an increase
in total small PG synthesis was confirmed. The increase
in 35SO4-GAG in response to TGF beta exceeded the
increase in 3H/35S-core protein by 1.4-fold, entirely con-
sistent with an increase in GAG chain length in addition to
a total increase in synthesis (not shown).
35SO4-biglycan, which eluted from DEAE columns with
both 0.3 and 1 M NaCl was present at lower levels than
decorin, and was not always clearly separated from the top
of the gel. It was not further characterized. Fibromodulin
substituted with KS has a mobility similar to decorin. Little
or no 35SO-PG or 3H/35S-PG remained after digestion with
chondroitinase ABC (Fig. 1), suggesting that newly syn-
thesized fibromodulin was below detectable levels in
these experiments. However, N-linked oligosaccharide-
substituted forms of fibromodulin lacking sulfate would
elute from DEAE columns at lower salt concentrations, less
than 0.3 M. Although small amounts of 3H/35S-proteins
consistent with N-linked oligosaccharide-substituted fibro-
modulin were found in the 0.2 M NaCl fraction, they were
not positively identified.
CHARACTERIZATION AND QUANTITATION OF TOTAL ENDOGENOUS
SMALL PGS BY WESTERN ANALYSIS AND CHEMILUMINESCENCE
Characterization by size and extent of glycosylation
The total decorin present after 16 days in control and
TGF beta 1-treated cultures were very similar in mobility
when identified by an anti-decorin antibody in Western
analysis (Fig. 2, panel 1), although small amounts of a
HMW decorin were detected by Western analysis in TGF
beta 1-treated cultures in some experiments (Fig. 2, panel
1, lanes 3 and 4, arrowheads). This decorin approached
the size of the newly synthesized decorin revealed by
isotope labeling. After digestion with chondroitinase ABC,
the sizes of the core proteins from control and TGF
beta-treated cultures were identical (Fig. 2, panel 2), con-
sistent with data shown for newly synthesized decorin in
Fig. 1. Most decorin was found with the GAG attached,
although a small amount of decorin-free core protein was
detected. In contrast, both native biglycan, with GAG at-
tached as well as free-biglycan core protein, were detected
in explanted cartilage (data not shown).
Native fibromodulins consisted of a diffuse population of
molecules ranging from approximately 60 to 100 kDa as is
the characteristic of KS substitution (Fig. 3, panel 1), and
also of a more discrete population near 66 kDa, which can
be seen more clearly when the native molecule is blotted to
nitrocellulose (Fig. 3, panel 2). When sulfated GAGs (KS)
were removed by enzymatic digestion from the core pro-
tein, a more compact band was detected at 66 kD indicat-
ing that the original sample did contain a subpopulation of
the core protein which was substituted with KS (Fig. 3,
panel 3). However, further removal of N-linked substituents
from the core protein with N-glycanase revealed that the
majority of the core protein was substituted with N-linked
oligosaccharide. After this step, fibromodulin was detected
as a major band at 46 kD and a minor band at 40 kD (Fig.
3, panel 4). These species were not detected in the native
extract; thus, fibromodulin is present in substituted KS-,
and N-linked oligosaccharide-substituted forms, but not as
a free-core protein. The total amounts of fibromodulin
changed as a result of TGF beta 1 treatment, but the
substitution of fibromodulin was similar in both control and
TGF beta 1-treated cultures.
Quantitation of total endogenous small PGs
For quantitation of total accumulated endogenous small
PGs (native as well as free-core protein), GAG chains were
removed from decorin and biglycan with chondroitinase
ABC and from fibromodulin with keratanase II, and the
resulting core proteins were blotted to nitrocellulose fol-
lowed by Western analysis [Figs. 2 (panel 2) and 3 (panel
3)], with quantitation using ECL (Figs. 4 and 5). No signifi-
cant changes in decorin and biglycan contents from day 2
to day 16 were detected in control cultures (Fig. 4). No
Table II
35SO4-decorin in articular cartilage explants cultured in the
presence or absence of TGF beta 1
Decorin
(cpm/mg wet)
HMW Decorin*
(cpm/mg wet)
Control
Day 2 1566 —
Day 16 370 124
+TGF beta 1
Day 2 1120 754
Day 16 729 4042
This table presents an analysis of newly synthesized decorin in
control and TGF beta 1-treated cultures on day 2 and on day 16,
both with respect to quantitative differences and with respect to
molecular weight. Cartilage was pulsed overnight on day 1 and on
day 15. Urea extracts were purified by DEAE anion exchange
chromatography, eluted with 0.3 and 1.0 M NaCl, and further
separated by 5–15% SDS gradient gel electrophoresis. Dried gels
were quantitated using a phosphorimager and MACBAS software
yielding relative amounts of newly synthesized decorin. Differ-
ences between control and TGF beta 1-treated cultures were
minimal at day 2, although some HMW decorin is already apparent
in cultures treated with TGF beta 1. By day 16, decorin synthesis
declined in controls, although some HMW decorin was detected. In
contrast, synthesis of HMW decorin dramatically increased in TGF
beta 1-treated cultures.
*HMW decorin has a mobility on SDS gels that is less than that
of decorin from controls.
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significant changes were detected for fibromodulin either,
but sample number (n2) was limited. A small, but signifi-
cant increase in decorin was detectable after 16 days of
culture in the presence of TGF beta 1 (Fig. 5). No signifi-
cant change in biglycan was detected in response to TGF
beta 1 (Fig. 5). Increases in fibromodulin in response to
TGF beta 1 were the most extensive averaging 3.8-fold
(Fig. 5).
Discussion
Our goal was to study the effects of TGF beta 1 on the
synthesis of three small PGs, decorin, biglycan, and fibro-
modulin by chondrocytes. To accomplish this, we chose the
conditions as close as possible to in vivo conditions by
using cartilage explants with an intact matrix, rather than
isolated chondrocytes in culture. We focused on small PGs,
specifically, by choosing culture conditions in which aggre-
can synthesis was not, or was only minimally, affected21.
Under these culture conditions, TGF beta 1 induces a
marked increase in fibronectin synthesis, which is one
characteristic of OA cartilage21. Thus, in these experi-
ments, we looked at the effect of TGF beta 1 on small PGs
Fig. 2. Western analysis of decorin in control and TGF beta
1-treated cartilage. Decorin present in cartilage extract was ana-
lyzed by SDS/PAGE and immunoblotting as the native molecule
(panel 1) and after removal of GAG chains by chondroitinase ABC
digestion (panel 2). Lanes 1 and 2 (duplicates) analyze 16-day
control cultures. Lanes 3 and 4 (duplicates) analyze samples from
TGF beta 1-treated samples after 16 days in culture. Native
samples were blotted to a positively charged membrane (Hybond–
N+, panel 1). Core proteins, resulting from digestion with chondroi-
tinase ABC, were blotted to nitrocellulose (panel 2). The blots were
probed with a rabbit polyclonal antibody raised against decorin
C-terminal peptide sequences. The arrowheads in panel 1 point to
a modest accumulation of HMW decorin in TGF beta 1-treated
culture.
Fig. 3. Western analysis of fibromodulin in control and TGF beta
1-treated cartilage. Fibromodulin present in cartilage extracts was
analyzed with a series of enzymatic digestions as described in
section Methods, in order to evaluate the extent of substitution with
KS and non-sulfated oligosaccharides. Analysis was done by
SDS/PAGE and immunoblotting. Lanes 1, 2 (duplicates) and 5, 6
(duplicates) are controls. Lanes 3, 4 (duplicates) and 7, 8 (dupli-
cates) are TGF beta-treated. Lanes 1–4 analyze 2-day cultures.
Lanes 5–8 analyze 16-day cultures. Note: the band that appears in
all blots above 100 kD is non-specific. Native PGs were blotted to
positively charged nylon (panel 1) or nitrocellulose (panel 2).
Nitrocellulose was also used for blotting following digestion of
native PGs with chondroitinase ABC and keratanase II (panel 3)
plus N-glycanase (panel 4). KS-substituted GAGs (wide bands)
can be seen in panel 1, and more faintly in panel 2. Fibromodulin,
after removal of KS, has a molecular weight of 66 kDa (panel 3),
indicating substitution with N-linked constituents, which can be
removed by N-glycanase, leaving the core proteins (panel 4).
Fibromodulin is present in partially KS-, partially non-sulfated
oligosaccharide-substituted forms, but not as a free-core protein.
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under conditions which support some of the characteristics
of the early OA phenotype. The entire cartilage used in this
study was disease-free, but since donor animals came from
a colony in which dogs of similar age and breed do develop
osteoarthritic lesions, the cartilage may have been pre-
disposed to develop OA. The source of this cartilage may
facilitate comparison of these results with OA cartilage in
the future. For the first time, we report a 3.8-fold increase
in fibromodulin in canine articular cartilage in response to
TGF beta 1, and we show that fibromodulin in canine
articular cartilage is partially substituted with KS.
The major newly synthesized small PG in cultures
treated with TGF beta 1 had a greater molecular weight
than endogenous decorin. This at first led to the hypothesis
that cartilage explants synthesized a novel CS/DS small
PG in response to TGF beta32. Subsequently, we identified
the HMW small PG as decorin. First, the HMW small PG
could be immunoprecipitated with an anti-decorin antibody,
which is specific for decorin with no cross-reactivity with
biglycan or fibromodulin in immunoblots24. Second, the
HMW small PG has GAG chains 1.5-fold larger than those
found in endogenous decorin, sufficient to account for the
increase in molecular weight. To explain the HMW small
PG, we could have postulated the presence of biglycan
with a single GAG chain. However, although biglycan with a
single GAG chain has a size similar to HMW decorin, we
observed no evidence for co-precipitation of any biglycan
with decorin in our experiments. Furthermore, it is not
necessary to postulate biglycan with a single GAG chain to
account for our results, which can also be explained by the
longer GAG chains on decorin. The effect of TGF beta on
GAG chain length has been reported previously; e.g., Chan
and Anastassiades33 reported an increase in length of
chondroitin sulfate chains synthesized in the presence of
TGF beta in high density bovine articular chondrocyte
cultures.
In our experiments, the majority of newly synthesized
small PGs in both control and TGF beta 1-treated explants
was decorin. Some biglycan was detected. Newly synthe-
sized, KS-substituted fibromodulin was below detectable
levels. This is consistent with the findings of Roughley34
that decorin synthesis greatly exceeds biglycan synthesis
in adult humans and with the ratio of mRNAs reported
by Cs-Szabo´ et al.11 for adult human cartilage (decorin:
biglycan:fibromodulin158:8:1). It is also consistent with
other experiments in our laboratory in which we have
isolated pure decorin from large quantities of articular
cartilage. Our estimated yield of 700 µg/g wet weight of
tissue agrees well with reports of Rosenberg et al.35.
Preliminary estimates put biglycan levels at 25–40% and
fibromodulin levels at 7–15% of decorin.
The three- to four-fold increase in 35SO4-decorin includ-
ing 1.5-fold increase in chain length in response to TGF
beta 1 from day 2 to day 16, with shift towards HMW
decorin, had little or no impact on total endogenous decorin
over this same time-period. Likewise, in control cultures,
synthesis of decorin declined from day 2 to day 16, but no
net decrease in total decorin content was observed by day
16 (Fig. 4). Thus, we must consider whether or not newly
synthesized decorin in culture and endogenous decorin
represent the same metabolic pool, and/or whether the
amount of decorin synthesized and lost during 2 weeks in
culture represents only a small proportion of endogenous
decorin. A half-life of 18 days has been reported for decorin
in bovine collateral ligament36, but additional work is
needed to establish this parameter for articular cartilage.
Endogenous fibromodulin content was more responsive
to culture with TGF beta than decorin and biglycan
Fig. 4. Effect of explant culture on content of small PGs in articular
cartilage. The figure represents a quantitative comparison of each
of the small PGs in control cultures between 2 days (white bars)
and 16 days (black bars) of incubation. At days 2 and 16, cartilage
was collected and extracted with guanidinium chloride. Extracts
were digested with chondroitinase ABC, or chondroitinase ABC
followed by keratanase II, prior to electrophoresis on 12% SDS
gels, and blotting to nitrocellulose membranes. The blots were
probed with rabbit polyclonal antibodies and immunoreactive
material was detected with ECL. Results of quantitation of the
signal on the film are presented graphically. The average of all
replicates for day 2 control cultures was set to 100. The data are
presented as mean±standard deviation. (n4 for decorin and
biglycan; n2 for fibromodulin). No significant change with time
was noted.
Fig. 5. Accumulation of decorin, biglycan, and fibromodulin in
articular cartilage in response to TGF beta 1. The figure represents
a quantitative comparison of each of the small PGs after 16 days in
culture in the absence (white bars) and in the presence (black
bars) of TGF beta 1. Core proteins were analyzed by Western
blotting as described inFig. 4. Results of quantitation are presented
graphically for day 16 samples. Data were obtained from two
different experiments for decorin and biglycan and from three
experiments for fibromodulin. The average of all replicates for day
16 control cultures was set equal to 100 in each experiment. The
data are presented as mean±standard deviation (n7 for decorin
and biglycan; n8 and 7, respectively, for fibromodulin). *indicates
differences that were significant at P<0.05.
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contents. In one experiment, a difference of as much as
seven-fold was noted. The greater net changes to fibro-
modulin mean that TGF beta can affect the relative com-
position of the small PGs with respect to each other. If
fibromodulin has a role in fibrillogenesis of collagen type II,
as has been demonstrated in transgenic mice for collagen
type I fibrillogenesis3, changes in the stoichiometry of
fibromodulin with respect to the other small PGs is likely to
have significant consequences.
KS chains are present on fibromodulin from bovine
cartilage obtained from cows from 3 months to 8 years
of age37. Fibromodulin in the human fetus and neonate is
a diffuse population of molecules between 70 and
110 kDa, consistent with KS substitution. In the human
adult, the electrophoretic pattern becomes more discrete
at 67 kDa. This corresponds to fibromodulin devoid of KS,
and in some instances, mature adult forms exist with
neither KS nor the non-sulfated polylactosamine22,34. Car-
tilage in this study came from the dogs that could be
characterized as adolescent or young adult. Native fibro-
modulin with KS substitution as well as fibromodulin
lacking KS were present in this cartilage. This is consist-
ent with the reported composition of human cartilage
of comparable age38,39; however, a function for these
endogenous free-core proteins in cartilage has not been
described.
Morales et al.40 reported that, in vivo, articular cartilage
contains a pool of TGF beta in excess of the amount of
exogenous, active TGF beta that must be added to ex-
plants to affect the PG synthesis. However, most of this
pool is sequestered and not readily accessible to the
chondrocyte. The release and activation of this reserve
after matrix degradation would allow for a role for TGF beta
in the progression of OA and could account for osteophyte
formation17,19. Does this postulated release and activation
of TGF beta actually occur in OA cartilage in vivo? If so,
over the extended time it may take for TGF beta 1-induced
changes in the cartilage matrix to accumulate, we would
expect to see elevated fibromodulin levels and a HMW
decorin in OA cartilage in vivo. In fact, increased fibromodu-
lin is observed in canine spontaneous and ACL transection
models, as well as in human cartilage41. One specimen
consisting of visually intact knee cartilage taken from a
canine knee joint that had extensive lesions did contain
a HMW decorin. However, two mild OA lesions showed no
evidence of a change in the size of decorin small PG. This
question will require further study.
An association of TGF beta with the progression of OA is
not intuitive. One expects an anabolic factor, such as TGF
beta to contribute to matrix repair. TGF beta should antag-
onize catabolic agents and restore aggrecan synthesis.
However, an increase in the synthesis of matrix compo-
nents may not be beneficial if the appropriate balance
cannot be maintained. Changes in the ratio of the small
PGs in cartilage, with respect to each other and to aggre-
can, could have a profound influence on the pathogenesis
of OA. For example, changes in the cartilage composition
of decorin and/or fibromodulin, which affect fibril diameter
could account for an early observation by Lust et al.42, who
reported that there is an absence of large diameter colla-
gen fibrils in OA lesions in cartilage from dogs with canine
hip dysplasia. Only medium and small diameter fibrils
remain. Furthermore, fibronectin, including the cartilage-
specific (VC) fibronectin isoform, is also elevated in OA
cartilage43,44. This isoform was demonstrated to bind more
decorin and biglycan than equivalent amounts of other
isoforms45. Thus, it is possible that fibronectin–small PG
complexes exist in OA cartilage to a degree in which they
do not occur in disease-free cartilage, and this could
influence matrix organization. Fibronectin–decorin inter-
actions influence fibrillogenesis of type I collagen5 and
might have a similar role with respect to type II collagen. It
is also interesting to note that sites capable of binding alpha
4 beta 1 integrins and small PGs have been found in close
proximity on fibronectin, suggesting functional cooperativ-
ity46. Chondrocytes from OA cartilage acquire expression
of the alpha 4 beta 1 integrin not normally present47. These
cell and matrix changes are likely to be reflected in changes
in gene expression in OA cartilage, but this remains
speculation at this point.
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